Filament Health Corp (NEO:FH, OTCQB:FLHLF), the psychedelic drug developer, has appointed Michael Messinger to its board of directors and as chairman of the audit committee.
Steven Nguyen has also been appointed as interim chief financial officer as Warren Duncan, the group’s former CFO, takes a medical leave of absence.
Nguyen has experience in accounting, tax and financial reporting across several industries and has spent four years on the audit team at Crowe MacKay.
Messinger brings 20 years of experience in finance roles at drug development and discovery organisations, having worked across a variety of therapeutic areas from neurology to immunology to infectious diseases.
Before his appointment, Messinger worked as chief financial officer at ContraFect, the drug developer, before becoming director of research and development finance at Lexicon Pharmaceuticals.
Filament chief executive officer Benjamin Lightburn said: "I am pleased to welcome Mr. Messinger to our Board of Directors.
"We welcome his many decades of experience in both finance and biotechnology and look forward to leveraging his expertise as we work to advance Filament's drug development platform."
Messinger added: “From the first meeting with the team at Filament, I was excited by the opportunity to work together.
"It is inspiring to find a group so committed to using psychedelics as a new therapeutic modality to treat some of our greatest mental health needs.”